20 June 2013
Keywords: Merck & Co, Vytorin, USA, FDA, Kidney disease patients
Article | 04 November 2011
US drug giant Merck & Co (NYSE: MRK) said yesterday that the Endocrinologic and Metabolic Drugs Advisory Committee of the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 November 2011
3 November 2011
19 June 2013
© 2013 thepharmaletter.com